Avineesh Singh 1 , Preeti Patel 1 , Vijay K Patel 1 , Deepak K Jain 1 , Ravichandran Veerasamy 2 , Prabodh C Sharma 3 , Harish Rajak 4 Show Affiliations »
Abstract
BACKGROUND: Colorectal cancer is a devastating disease with a dismal prognosis which is heavily hampered by delayed diagnosis. Surgical resection, radiation therapy and chemotherapy are the curative options. Due to few therapeutic treatments available i.e., mono and combination therapy and development of resistance towards drug response, novel and efficacious therapy are urgently needed. OBJECTIVE: In this study, we have studied the potential of histone deacetylase inhibitors in colorectal cancer. RESULTS: Histone deacetylase inhibitors (HDACIs) are an emerging class of therapeutic agents having potential anticancer activity with minimal toxicity for different types of malignancies in preclinical studies. HDACIs have proven less effective in monotherapy thus the combination of HDACIs with other anticancer agents are being assessed for the treatment of colorectal cancer. CONCLUSION: The molecular mechanism emphasizing the anticancer effect of HDACIs in colorectal cancer was illustrated and a recapitulation was carried out on the recent advances in the rationale behind combination therapies currently underway in clinical evaluations. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
BACKGROUND: Colorectal cancer is a devastating disease with a dismal prognosis which is heavily hampered by delayed diagnosis. Surgical resection, radiation therapy and chemotherapy are the curative options. Due to few therapeutic treatments available i.e., mono and combination therapy and development of resistance towards drug response, novel and efficacious therapy are urgently needed. OBJECTIVE: In this study, we have studied the potential of histone deacetylase inhibitors in colorectal cancer . RESULTS: Histone deacetylase inhibitors (HDACIs) are an emerging class of therapeutic agents having potential anticancer activity with minimal toxicity for different types of malignancies in preclinical studies. HDACIs have proven less effective in monotherapy thus the combination of HDACIs with other anticancer agents are being assessed for the treatment of colorectal cancer . CONCLUSION: The molecular mechanism emphasizing the anticancer effect of HDACIs in colorectal cancer was illustrated and a recapitulation was carried out on the recent advances in the rationale behind combination therapies currently underway in clinical evaluations. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Entities: Disease
Keywords:
Colorectal cancer; HDAC inhibitors; fluoropyrimidines; kinase inhibitors; proteasome inhibitors; topoisomerasezzm321990inhibitors
Mesh： See more »
Substances： See more »
Year: 2017
PMID： 28067178 DOI： 10.2174/1568009617666170109150134
Source DB: PubMed Journal: Curr Cancer Drug Targets ISSN： 1568-0096 Impact factor: 3.428